Honey is increasingly recognized for its bioactive properties beyond nutrition. Rich in flavonoids, phenolic acids, and enzymes, it helps reduce reactive oxygen species (ROS) and modulates pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β. These pathways are central to vascular inflammation and endothelial dysfunction, both of which contribute to hypertension. By enhancing nitric oxide (NO) bioavailability, honey supports vasodilation and improved vascular tone. Its influence on lipid metabolism and glycemic control further strengthens cardiovascular health.
While promising, honey should be considered a complementary intervention rather than a substitute for established antihypertensive therapies. More controlled clinical trials are needed to define optimal dosage, long-term safety, and population-specific efficacy.
What are your thoughts on natural bioactive compounds like honey to be integrated more systematically into hypertension management strategies? Suggest other natural compounds that can be integrated for hypertension management.
Natural bioactive compounds like honey are interesting, especially because they contain antioxidants and polyphenols that may support vascular health. But honey is still a sugar source and must be used cautiously, especially in patients with metabolic risks.
Integrating natural bioactive compounds into hypertension management is a promising adjunct strategy, but best used as complementary, not replacement therapy, especially for patients with moderate to severe hypertension.
Use of Natural compounds like Honey as Intervention for clinical therapies seems to be less feasible due to regulatory demands. Meeting regulatory compliance is a far stretch since natural products have an inherent tendency to have inconsistency in composition, making it difficult to standardise.
A natural compound that can effectively control hypertension is extremely significant. However, today’s honey is available in adulterated forms, preventing us from experiencing its therapeutic effects.